MB

Premier Health’s Subsidiary Canadian Health Care Agency Awarded Contracts Valued at $23m

Retrieved on: 
Wednesday, November 22, 2023
First Nations, Indigenous Services Canada, Nurse practitioner, ISC, PHA, MB, Registered nurse, Nursing

MONTREAL, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leader in healthcare services and technologies, is pleased to announce that its wholly-owned subsidiary, Cambridge based Canadian Health Care Agency (“CHCA”), has been retained as a primary contractor for 4-year contracts with Indigenous Services Canada (“ISC”).

Key Points: 
  • MONTREAL, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leader in healthcare services and technologies, is pleased to announce that its wholly-owned subsidiary, Cambridge based Canadian Health Care Agency (“CHCA”), has been retained as a primary contractor for 4-year contracts with Indigenous Services Canada (“ISC”).
  • The contracts were awarded on November 3 and are to transition in early 2024.
  • Indigenous Services Canada (ISC) works collaboratively with partners to improve access to high quality services for First Nations, Inuit, and Métis.
  • ISC’s vision is to support and empower Indigenous people to independently deliver and address the socio-economic conditions in their communities.

Kia Communities in Motion Continues to Inspire Positive Change in Canadian Communities

Retrieved on: 
Wednesday, November 22, 2023
Conference, Food, Movement, Freedom, Student, Squamish Nation, Kia Canada, Organic, Education, Housing, Climate change, MB, Kia, Organization, Audience award, Community, Renewable energy

TORONTO, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Kia Communities in Motion, a transformative grassroots initiative, in collaboration with Community Foundations of Canada, have been working alongside seven local charities and non-profits throughout year two of the program to support innovative projects that foster inclusivity, promote movement, and drive positive change in communities across the country.

Key Points: 
  • English teacher Marina hosts language classes put on by the Parkland Ukrainian Family Fund, which are made possible by the Kia Communities in Motion initiative.
  • The sustained success of this initiative underscores Kia Canada’s unwavering dedication to shape a future where all individuals can thrive.
  • “The charitable organizations within the Kia Communities in Motion program represent a diverse range of causes.
  • Their work, dedicated to addressing the unique needs of their communities, epitomizes inclusivity and shows how positive change can be made at the local level.”
    The 2023 recipients have already enacted meaningful change in their communities.

EnerPure Inc. closes oversubscribed CAD$5 million financing

Retrieved on: 
Monday, November 20, 2023
Recycling, CFO, NOT, GHG, CAD, News, Engineering, Unit, MB, Face, Growth

Winnipeg, MB, Nov. 20, 2023 (GLOBE NEWSWIRE) -- EnerPure Inc. (“EnerPure” or the “Company”), a Manitoba cleantech company, is pleased to announce that it has now closed its oversubscribed CAD$5 million financing as described in its October 23, 2023, news release. In total, the Company raised over CAD$6.9 million through the issuance of 12,600,495 units.

Key Points: 
  • NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRES
    Winnipeg, MB, Nov. 20, 2023 (GLOBE NEWSWIRE) -- EnerPure Inc. (“EnerPure” or the “Company”), a Manitoba cleantech company, is pleased to announce that it has now closed its oversubscribed CAD$5 million financing as described in its October 23, 2023, news release.
  • In total, the Company raised over CAD$6.9 million through the issuance of 12,600,495 units.
  • Todd Habicht, CEO and Founder commented: “We have always believed that recycling can and should be part of the energy transition.
  • A special thanks to Marshall and his team in completing this oversubscribed financing.”, noted Damian Towns, CFO.

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Retrieved on: 
Thursday, December 28, 2023
Biotechnology, Natural Resources, Pharmaceutical, General Health, Health, Mental Health, Cannabis, Clinical Trials, Pulmonary fibrosis, IND, HTR, Depression, Half-life, Mouse, Brain, Human, Addiction, Clinical trial, Investigational New Drug, Anxiety, Hallucination, Behavior, Artificial intelligence, MB, Toxicity, Permeability, Therapy, DMT, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has named EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has named EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series.
  • Enveric plans to initiate preclinical development of EB-003 in early 2024 in preparation for an Investigational New Drug (IND) application for a first-in-human clinical trial.
  • HTR is a rodent behavioral model used to predict whether a molecule is likely to produce hallucinogenic effects in humans.
  • From the top three candidates, EB-003 was chosen as lead based on its superiority in numerous relevant measures.

Datalogic invests in Oversonic Robotics, continuing its commitment to Artificial Intelligence

Retrieved on: 
Thursday, December 21, 2023
Research and development, Marketing, Attention, Health care, Transport, Robotics, Health, Euronext, Patent, Artificial intelligence, MB, Growth, Entrepreneurship, Safety, Intelligence, Algorithm, Creativity, Environment, Typesetting

BOLOGNA, Italy, Dec. 21, 2023 /PRNewswire-PRWeb/ -- Datalogic S.p.A. (Borsa Italiana S.p.A.: DAL), a company listed on the Euronext STAR Milan of Borsa Italiana S.p.A. and a global leader in automatic data capture and industrial automation markets, announces that through its subsidiary Datalogic S.r.l., it has acquired a minority stake in Oversonic Robotics Srl Benefit Corporation ("Oversonic Robotics"), an innovative software company that develops cognitive computing systems for robotics. Oversonic Robotics has developed RoBee, the first humanoid robot certified to support work in manufacturing facilities of companies with an Industry 5.0 perspective. RoBee can easily perform tasks that could otherwise be detrimental to the health of human workers, both physically and mentally.

Key Points: 
  • Datalogic, a global leader in industrial automation products and solutions, is committed to investing in cutting-edge industrial innovation.
  • In particular, Datalogic and Oversonic Robotics will partner on sales, R&D, and marketing activities.
  • "We are excited to partner with Oversonic Robotics, an Italian company with great experience in creating humanoid robots with artificial intelligence algorithms.
  • Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U.

Canada Life gives back to Canadian charities with holiday gifts

Retrieved on: 
Wednesday, December 20, 2023
MB, Ronald McDonald House Charities, Investment, RMHC, Organic, Child, Nursing

WINNIPEG, MB, Dec. 20, 2023 /CNW/ - Canada Life today announced community investments to Ronald McDonald House Charities (RMHC), Children's Aid Foundation of Canada and YMCA Canada.

Key Points: 
  • WINNIPEG, MB, Dec. 20, 2023 /CNW/ - Canada Life today announced community investments to Ronald McDonald House Charities (RMHC), Children's Aid Foundation of Canada and YMCA Canada.
  • Canada Life employees chose these charities to receive financial support as part of the company's annual Holiday Gift campaign.
  • Since 2003, Canada Life has delivered over $1 million to 82 charities during a time of year when charities are looking for help to support all those who are seeking their services.
  • "At Canada Life, we believe in coming together to enrich lives and strengthen communities," says Jeff Macoun, President and Chief Operating Officer, Canada Life.

Canadian Kraft Paper Industries Limited fined $1 million for unlawful deposit of effluent into the Saskatchewan River

Retrieved on: 
Monday, December 18, 2023
Biophysical environment, Climate change, Fund, Government, Gekkoninae, Government of Canada, Fisheries Act, Court, Environment, Health, Registry, Pulp, PAS, Fishery, Water, MB, Committee, Safety, Saskatchewan River

The charges stemmed from a February 2019 pipe leak at Canadian Kraft Paper Industries Limited's pulp and paper mill in The Pas, Manitoba.

Key Points: 
  • The charges stemmed from a February 2019 pipe leak at Canadian Kraft Paper Industries Limited's pulp and paper mill in The Pas, Manitoba.
  • The leak resulted in the release of 23,000 litres of black liquor, a by-product of the manufacturing process, into Canadian Kraft Paper Industries Limited's mill effluent treatment system.
  • Through a subsequent investigation, they determined that over the course of six days, close to 181 million litres of acutely lethal effluent had been released from the effluent treatment system into the Saskatchewan River.
  • Subsection 6(5) of the Pulp and Paper Effluent Regulations does not allow the deposit of effluent when the effluent is acutely lethal to fish.

Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP

Retrieved on: 
Wednesday, December 13, 2023
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Surgery, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, PPCB, Lung, PRP, Pancreatic cancer, Prostate, Breast, Brain, Skin, OTC Markets Group, US Foods, Liver, Trypsinogen, Patient, Kidney, Neoplasm, Interview, MB, MD, Cancer, Georgetown University Medical Center, Survival, Growth, Chymotrypsinogen, Pharmaceutical industry

Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.

Key Points: 
  • Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.
  • “Chemotherapy is still considered an irreplaceable front-line therapeutic strategy to treat cancer.
  • But multidrug resistance represents a common hurdle that profoundly compromises clinical outcomes, especially in pancreatic cancer.
  • Tumor resistance to frontline chemotherapy means a poor prognosis for survival, especially in pancreatic cancer.

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting

Retrieved on: 
Tuesday, November 21, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Medicine, International League Against Epilepsy, Dravet syndrome, American Epilepsy Society, Annual general meeting, Therapy, Language, Patient, Movement, Seizure, MB, Speech, Neurology, Epilepsy, AES, Safety, Pharmaceutical industry, Pediatric nursing

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that presentations related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1 – 5, in Orlando, Florida.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that presentations related to the Company’s work in Dravet syndrome will be presented at the American Epilepsy Society (AES) 2023 Annual Meeting, taking place December 1 – 5, in Orlando, Florida.
  • The company is advancing STK-001 as potentially the first medicine to address the genetic cause of Dravet syndrome.
  • “People living with Dravet syndrome typically experience high rates of seizures and debilitating effects on neurodevelopment, including behavioral and developmental delays, movement and balance issues, and delayed language and speech, among other life-altering challenges, which current treatments do not adequately address,” said Barry Ticho, M.D., Ph.D., Chief Medical Officer of Stoke Therapeutics.
  • “We look forward to sharing the findings from more than 3 years of clinical studies, including important new data from the longest and largest prospective natural history study of patients with Dravet syndrome, which showed that despite treatment with multiple anti-seizure medicines, most patients continued to experience convulsive seizures over 24 months and that gaps in neurodevelopment persist between children with Dravet syndrome and their neurotypical peers.

Cyberlux Corporation (OTC: CYBL) Releases Third Quarter 2023 Financial and Operational Results; Announces Transformative Actions to Refocus the Company on the Defense Technology Sector

Retrieved on: 
Tuesday, November 21, 2023
Contracts, Defense, Other Defense, Aircraft, Acquisition, Operation Sky Monitor, Defense Logistics Agency, Corporation, ADS, Telecommunications, Growth, Government agency, Government, Safariland, Agreement, SDR, ISR, Partnership, OTC, Aircraft systems, Advanced Intelligent Tape, FBD, USSOCOM, Hardware, JITC, USAI, SAS, UAS, OTC Markets Group, Security, Communication, Publishing, HF, MCT, CYBL, CE, MB, Software, VHF, Human, Dedicated short-range communications, Cryptocurrency, Satellite navigation device, Cassette tape, United States Army, Perception, Reconnaissance

Our operating period ended September 30, 2023, has set the stage for the Company to capitalize on remarkable opportunities across the global Defense Technology markets.

Key Points: 
  • Our operating period ended September 30, 2023, has set the stage for the Company to capitalize on remarkable opportunities across the global Defense Technology markets.
  • Our work to remove the CE designation continues, but the Company is driving breakthrough results regardless of these temporary obstacles.
  • As the Company develops advanced technology products, we will identify core technology and product companies, and these companies will become the Cyberlux growth catalysts.
  • As the results show, Cyberlux is building a global enterprise and developing into a leading technology growth company.